Coherus BioSciences Partners with Zumutor on Phase 1 Cancer Immunotherapy Study
This article was created with the help of artificial intelligence.
Key Takeaways
- Coherus BioSciences and Zumutor Biologics will conduct a Phase 1 study examining ZM008 in combination with LOQTORZI.
- ZM008 is a monoclonal antibody against the LLT1 protein, which acts as an NK checkpoint and inhibits natural killer cells.
- By blocking LLT1, ZM008 is intended to release the brake on the immune response against cancer cells.
- The collaboration includes a clinical collaboration and a supply agreement between the two companies.
- NK-cell-directed immunotherapies represent a newer approach that differs from established PD-1 or CTLA-4 inhibitors.
Coherus BioSciences (NASDAQ: CHRS) announced a clinical collaboration with Zumutor Biologics on June 23, 2026. The two companies will conduct a Phase 1 study examining the investigational drug ZM008 in combination with Coherus' LOQTORZI.
What does the clinical study examine?
ZM008 is a monoclonal antibody directed against the LLT1 protein. LLT1 acts as an NK checkpoint – a molecular mechanism that inhibits the activity of natural killer cells. Natural killer cells are part of the innate immune system and play an important role in combating tumor cells. By blocking LLT1, ZM008 is intended to release this brake and enhance the immune response against cancer cells.
LOQTORZI is a Coherus BioSciences drug used in oncology. The combination of both drugs is to be tested in the Phase 1 study for safety, tolerability, and initial efficacy signals.
Which companies are involved?
Coherus BioSciences is a publicly traded US biotechnology company focused on biosimilars and oncology therapeutics. The company's stock is traded on NASDAQ under the ticker symbol CHRS.
Zumutor Biologics describes itself as an immuno-oncology biotechnology company and develops next-generation checkpoint inhibitors. The company focuses on the modulation of NK cells – an area that has been less intensively researched in cancer immunotherapy compared to T-cell-directed approaches.
What does the agreement include?
The collaboration comprises two components: a clinical collaboration for conducting the Phase 1 study and a supply agreement. Coherus BioSciences will provide LOQTORZI for the combination therapy, while Zumutor will contribute ZM008.
Details regarding study financing, potential milestone payments, or the allocation of future rights were not disclosed in the announcement of June 23, 2026.
Classification for the DACH region
For investors in the German-speaking region, Coherus BioSciences is tradable on US exchanges. The company belongs to the biotechnology sector, which is typically characterized by high development risks and lengthy approval processes. Phase 1 studies are early clinical trials in which safety and dosage are primarily tested – it typically takes years until possible market maturity.
NK-cell-directed immunotherapies represent a newer approach that differs from established PD-1 or CTLA-4 inhibitors. Whether this approach proves effective in later study phases cannot be assessed at this time.